Melanie Thompson: So, what’s in the HIV pipeline?

Did you know that people with HIV can live a normal—or even longer—lifespan if they get on treatment early and take it consistently? This awesome news is made possible by potent drugs that suppress HIV to low l...
article placeholder

AIDS Research Consortium of Atlanta settles into new home

https://cdn.thegavoice.com/images/stories/6-11-10/melanie-thompson-body-6-11-10.jpg

Founded in 1988, the AIDS Research Consortium of Atlanta is one of Atlanta’s oldest continuously operating HIV/AIDS service organizations.

The agency learned in mid-September it would be forced from its home on Ponce de Leon Avenue after its building was purchased by a real estate developer who planned to build new residential properties.

The move to ARCA’s new location at 440 Ralph McGill Blvd. has been challenging, Dr. Melanie Thompson, ARCA executive director, told GA Voice.

“We were given about eight weeks, but it took us a long time to find a place where we wanted to live, given all the different constraints,” Thompson said. “We had been in our old place 22 years. You can imagine how much stuff accumulates over 22 years.”

article placeholder

Operation MOVE ARCA needs $10k to help HIV agency find new home

The AIDS Research Consortium of Atlanta is being forced out of its office space on Ponce de Leon Avenue after the facility it has rented for 22 years was sold to real estate developers, the organization recently announced via its Facebook page.

ARCA, founded in 1988, focuses on HIV treatment and prevention research, as well as free HIV/STD testing services. Thousands of Atlantans have participated in more than 75 trials at ARCA, according to its website. “Our trials have contributed to the licensing by the FDA of 25 HIV/AIDS therapies that have been responsible for a dramatic increase in the length and quality of life for persons with HIV,” the agency states.

ARCA's currently facilities are located at 131 Ponce de Leon Ave., NE, between Ponce and North Avenue. The organization has been given until Oct. 22 to vacate the current space and needs some $10,000 to make the move happen, the group announced.

article placeholder

HIV researcher moves forward with vaccine trial

GeoVax Labs, an Atlanta-based biotechnology company, today announced a major milestone in its quest to eliminate the HIV virus, as the first patient has been inoculated with the company's HIV/AIDS vaccine following success in post-vaccine viral control in primates.

The company's vaccine is aimed at stimulating the body's immune system to resist the spread of infection.

"Dosing the first study participant marks a major milestone for our Phase 1/2 clinical trial. We are pleased to have the AIDS Research Consortium of Atlanta, the Alabama Vaccine Research Center at the University of Alabama, Birmingham, and the AIDS Research Alliance of Los Angeles participating in the trial,” said Robert McNally, president and CEO of GeoVax Labs, in a prepared statement.

“These three trial sites are actively seeking persons who are interested in and fit the criteria for the study," McNally added.

article placeholder

ARCA seeks volunteers for historic HIV vaccine trial

ARCA principal investigator Dr. Melanie Thompson

The AIDS Research Consortium of Atlanta is currently seeking 10 to 12 volunteers to help test the safety of a vaccine that shows the potential of reversing HIV viral loads in HIV-positive individuals.

The 77-week trial of a vaccine from GeoVax, a biotechnology company based in Smyrna, Ga., that specializes in developing an HIV vaccine, is the first of its kind.

This study is “the first therapeutic trial ever conducted using a promising HIV vaccine candidate from GeoVax, Inc.,” according to a May 18 press release from ARCA.